Health · Pharma & Biotech · 1 hr ago
HLB Therapeutics' US trial of eye treatment misses main efficacy goal
HLB Therapeutics said its RGN-259 eye-drop candidate missed the main goal in a US phase 3 trial.
The test, run by its US subsidiary RegeneTree, found no statistically significant difference in healing rates after four weeks between people given RGN-259 and those given a placebo.
The candidate is being developed to treat neurotrophic keratitis, a rare eye disease in which damaged corneal nerves reduce sensation and the eye’s ability to heal itself.
RGN-259 contains thymosin beta-4, a protein intended to promote tissue repair and nerve regeneration.
The candidate also failed to show statistical efficacy in a European phase 3 trial, according to the company.
HLB Therapeutics plans to review the full results, including secondary measures and responses in subgroups, before deciding on its development plans and any next steps.
HLB Therapeutics said its US phase 3 trial of RGN-259 did not meet its primary efficacy goal.
The trial found no statistically significant difference in healing rates between patients given RGN-259 and those given a placebo four weeks after treatment.
The company received the trial’s topline results from a contract research organization on November 13.
HLB Therapeutics plans to analyze the full results, including secondary measures and responses in subgroups, before deciding on next steps.
RGN-259 also failed to show statistical efficacy in a European phase 3 trial.
- Who
- HLB Therapeutics and its US subsidiary, ReGenTree, which conducted the trial.
- What
- The US phase 3 trial of RGN-259 failed to show a statistically significant difference on its primary measure.
- When
- HLB Therapeutics reported the result on November 16, 2026; it received the topline results on November 13.
- Where
- The United States.
- Why
- The trial did not show a statistically significant difference in healing rates between the treatment and placebo groups four weeks after treatment.
This story does not have two clearly opposing sides.
HLB Therapeutics received topline results from the contract research organization.
HLB Therapeutics reported that RGN-259 had not met the trial’s primary efficacy measure.
- Drug candidate
- RGN-259
- Trial
- US phase 3
- Primary measure
- Healing rate four weeks after treatment
- Result
- No statistically significant difference between RGN-259 and placebo
- Next steps
- Analyze full results, secondary measures and subgroup responses
What people are saying
분석 결과를 바탕으로 향후 개발 방향과 계획을 신중하게 검토하고, 필요한 후속 조치를 신속하고 책임 있게 추진하겠다